---
title: "East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278712777.md"
description: "East China Pharmaceutical's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received FDA approval for a Phase I clinical trial in the U.S. The trial will focus on the injectable drug HDM2024, aimed at treating advanced solid tumors. This approval is a significant milestone for the company's international research and development efforts."
datetime: "2026-03-11T11:26:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278712777.md)
  - [en](https://longbridge.com/en/news/278712777.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278712777.md)
---

# East China Pharmaceutical Subsidiary Receives FDA Approval for Clinical Trial

East China Pharmaceutical announced that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I clinical trial in the United States. According to Jin10, the trial will focus on the injectable drug HDM2024, which is intended for the treatment of advanced solid tumors. This approval marks a significant step for the company in expanding its research and development efforts internationally.

### Related Stocks

- [000963.CN](https://longbridge.com/en/quote/000963.CN.md)

## Related News & Research

- [00:18 ETDatar Cancer Genetics erhält wegweisende FDA-Zulassung in den USA für CellDx-Tissue - umfassender Genomprofiling-Test für solide Tumoren](https://longbridge.com/en/news/286712658.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)
- [20:00 ETFull-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities](https://longbridge.com/en/news/286830045.md)
- [Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth](https://longbridge.com/en/news/286593782.md)
- [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md)